Fact CheckerSign in

NCT06117384Recruiting

Systems Oncology Approach to Optimize Ovarian Cancer Treatment

Source: ClinicalTrials.gov · Last updated 7 Nov 2023 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The overall aim is to identify effective therapeutic strategies to ovarian cancer (OC) using serial tumor, ascites and blood samples, and carry out state-of-the-art sequencing approaches, functional assays and associated bioinformatics to understand mechanisms behind chemoresistance in OC and identify new treatment options for OC patients. In this observational trial, we will systematically collect, analyze and interpret functional, molecular and clinical data from real-world ovarian cancer patients.

Status (registry)
Recruiting
Study type
Observational
Enrollment
500 (estimated)
First submitted
21 Oct 2023
Start date
Jan 2022
Primary completion date
Dec 2027
Lead sponsor
University of Helsinki
NCT number
NCT06117384

What you commit to

  • Study type: Observational
  • Planned participants: 500
  • From Jan 2022 to the primary completion date, Dec 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Inability to consent to the study

Who the study is looking for

  • Patients diagnosed with ovarian cancer
  • Available tumor tissue/blood samples

Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Helsinki University and Helsinki University Hospital
Coordinator of this site? Confirm its status
HelsinkiFinlandRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.